Méndez OA

Idioma: Español
Referencias bibliográficas: 18
Paginas: 182-187
Archivo PDF: 115.88 Kb.

RESUMEN

El abordaje en el estudio y tratamiento de la insuficiencia cardíaca ha sido dirigido predominantemente a la activación neuroendocrina, con el uso de agentes terapéuticos que contrarrestan dichas alteraciones, como IECAs, betabloqueadores, aldosterona, antagonistas AT, con resultados satisfactorios a mediano plazo, en poblaciones controladas en estudios multicéntricos. No obstante, el beneficio a largo plazo parece reducirse, y la enfermedad avanza a estadios terminales. El presente escrito, revisa otros mecanismos de daño miocárdico y las medidas preventivas potenciales para incorporarse al manejo estandarizado de la insuficiencia cardíaca.

REFERENCIAS (EN ESTE ARTÍCULO)

1. HUNT SA, ET AL: ACC/AHA Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article. Circulation 2005; 112: 1825-1852.

2. FOO RS, MANI K, KITSIS RN: Death begets failure in the heart. J Clin Invest 2005: 115; 565-571. 3. BENNETT MR: Apoptosis in the cardiovascular system. Heart 2002; 87: 480-487.

3. OLIVETTI G, ET AL: Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.

4. WENCKER D, ET AL: A mechanistic role for cardiomyocyte apoptosis in heart failure. Cell; 2003: 1497-1504.

5. MACCARTHY PA, SHAH AM: Oxidative stress and heart failure. Coronary Artery Disease. 2003; 14: 109-113.

6. MCMURRAY J, CHOPRA M, ABDULLAHI, SMITH WE, DARGIE HJ: Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493-1498.

7. XIE YW, KAMINSKI PM, WOLIN MS: Inhibition of cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation. Circ Res 1998; 82: 891-897.

8. HARE JM: Oxidative stress and apoptosis in heart failure progression. Circ Res 2001; 89: 198-200.

9. YUSUF F, DAGENIAS G, POGUE J, BOSH J, SLIGHT P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160.

10. PARRILLO JE, BURCH C, SHELLHAMER JH, ET AL. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985; 76: 1539-53.

11. KAPADIA S, TORRE-AMIONE G, YOKOHAMA T, ET AL: TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am J Physiol 1995; 268: H517-25.1

12. BOZKURT B, TORRE-AMIONE G, WARREN MS, ET AL: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.

13. BAUERSACHS J, FRACCAROLLO D, SCHAFER A, ERTL G: Angiotensin-Converting Enzyme Inhibition and Endothelin Antagonism for Endotelial Dysfunction in Heart Failure: Mono- or Combination Therapy. J Cardiovasc Pharmacol 2002; 40: 594-600.

14. KAYE D, AHLERS B, AUTELIANOD, CHIN-DUSTIN J. In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure. Circulation 2000; 102: 2707-2712.

15. LÓPEZ A, CASADO S: Heart Failure, Redox Alterations, and Endotelial Dysfunction. Hypertension 2001; 38: 1400-1405.

16. ROSSIG L, HOFFMANN J, HUGEL B, MALLAT Z, HAASE A, FREYSSINET JM, ET AL: Vitamin C Inhibits Endothelial Cell Apoptosis in Congestive Heart Failure. Circulation 2001; 104: 2182-2187.

17. FANG Z, MARWICK T: Vascular dysfunction ang heart failure: Epiphenomenon or etiologic agent? Am Heart J 2002; 143: 383-390.

18. MACDONALD J, KENNEDY N, STRUTHERS A: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-770.